Search

Your search keyword '"Dong M. Shin"' showing total 568 results

Search Constraints

Start Over You searched for: Author "Dong M. Shin" Remove constraint Author: "Dong M. Shin"
568 results on '"Dong M. Shin"'

Search Results

1. Beyond Cancer Cells: How the Tumor Microenvironment Drives Cancer Progression

2. Associations of inflammation with neuropsychological symptom cluster in patients with Head and neck cancer: A longitudinal study

3. Incidence trends of squamous cell carcinoma of the head and neck (SCCHN) in the aging population––A SEER‐based analysis from 2000 to 2016

4. Cisplatin-mediated activation of glucocorticoid receptor induces platinum resistance via MAST1

5. Tumor Membrane Vesicle Vaccine Augments the Efficacy of Anti-PD1 Antibody in Immune Checkpoint Inhibitor-Resistant Squamous Cell Carcinoma Models of Head and Neck Cancer

6. Chloride Influx of Anion Exchanger 2 Was Modulated by Calcium-Dependent Spinophilin in Submandibular Glands

7. The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma

8. Molecular Characterization and Clinical Relevance of Metabolic Expression Subtypes in Human Cancers

9. Genomic and Molecular Landscape of DNA Damage Repair Deficiency across The Cancer Genome Atlas

10. Pan-Cancer Analysis of lncRNA Regulation Supports Their Targeting of Cancer Genes in Each Tumor Context

11. Spatial Organization and Molecular Correlation of Tumor-Infiltrating Lymphocytes Using Deep Learning on Pathology Images

12. Driver Fusions and Their Implications in the Development and Treatment of Human Cancers

13. Somatic Mutational Landscape of Splicing Factor Genes and Their Functional Consequences across 33 Cancer Types

14. Systematic Analysis of Splice-Site-Creating Mutations in Cancer

15. Machine Learning Detects Pan-cancer Ras Pathway Activation in The Cancer Genome Atlas

16. Integrated Genomic Analysis of the Ubiquitin Pathway across Cancer Types

17. Genomic, Pathway Network, and Immunologic Features Distinguishing Squamous Carcinomas

18. Outcomes Stratification of Head and Neck Cancer Using Pre- and Post-treatment DNA Methylation From Peripheral Blood

21. Supplementary Figure 1 from Combination of Anti-HER3 Antibody MM-121/SAR256212 and Cetuximab Inhibits Tumor Growth in Preclinical Models of Head and Neck Squamous Cell Carcinoma

22. Supplementary Figure 2 from Combination of Anti-HER3 Antibody MM-121/SAR256212 and Cetuximab Inhibits Tumor Growth in Preclinical Models of Head and Neck Squamous Cell Carcinoma

23. Supplementary Materials and Methods, Table 1 from Combination of Anti-HER3 Antibody MM-121/SAR256212 and Cetuximab Inhibits Tumor Growth in Preclinical Models of Head and Neck Squamous Cell Carcinoma

24. Supplementary Figure 3 from Combination of Anti-HER3 Antibody MM-121/SAR256212 and Cetuximab Inhibits Tumor Growth in Preclinical Models of Head and Neck Squamous Cell Carcinoma

26. Supplementary Figure 4 from Combination of Anti-HER3 Antibody MM-121/SAR256212 and Cetuximab Inhibits Tumor Growth in Preclinical Models of Head and Neck Squamous Cell Carcinoma

27. Supplementary Figure 5 from Combination of Anti-HER3 Antibody MM-121/SAR256212 and Cetuximab Inhibits Tumor Growth in Preclinical Models of Head and Neck Squamous Cell Carcinoma

28. Data from Combination of Anti-HER3 Antibody MM-121/SAR256212 and Cetuximab Inhibits Tumor Growth in Preclinical Models of Head and Neck Squamous Cell Carcinoma

30. Data from A Correlative Analysis of PD-L1, PD-1, PD-L2, EGFR, HER2, and HER3 Expression in Oropharyngeal Squamous Cell Carcinoma

33. Commentary on This Article from Chemoprevention of Head and Neck Cancer with Celecoxib and Erlotinib: Results of a Phase Ib and Pharmacokinetic Study

34. Supplementary Figures 6 - 7 from Combination of Anti-HER3 Antibody MM-121/SAR256212 and Cetuximab Inhibits Tumor Growth in Preclinical Models of Head and Neck Squamous Cell Carcinoma

35. Data from In Vitro and In Vivo Synergistic Antitumor Activity of the Combination of BKM120 and Erlotinib in Head and Neck Cancer: Mechanism of Apoptosis and Resistance

36. Pembrolizumab and cabozantinib in recurrent metastatic head and neck squamous cell carcinoma: a phase 2 trial

37. Supplementary Table from Phase Ib Study of Chemoprevention with Green Tea Polyphenon E and Erlotinib in Patients with Advanced Premalignant Lesions (APL) of the Head and Neck

38. Honokiol Radiosensitizes Squamous Cell Carcinoma of the Head and Neck by Downregulation of Survivin from Honokiol Radiosensitizes Squamous Cell Carcinoma of the Head and Neck by Downregulation of Survivin

41. Supplementary Figure 1 from HER3 Targeting Sensitizes HNSCC to Cetuximab by Reducing HER3 Activity and HER2/HER3 Dimerization: Evidence from Cell Line and Patient-Derived Xenograft Models

42. Supplementary Data and Methods from Modulation of Bax and mTOR for Cancer Therapeutics

44. Data from Modulation of Bax and mTOR for Cancer Therapeutics

45. Data from Phase Ib Study of Chemoprevention with Green Tea Polyphenon E and Erlotinib in Patients with Advanced Premalignant Lesions (APL) of the Head and Neck

46. Data from Phase II Multi-institutional Clinical Trial Result of Concurrent Cetuximab and Nivolumab in Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma

48. Supplementary Tables 1 - 3 from RRM2 Regulates Bcl-2 in Head and Neck and Lung Cancers: A Potential Target for Cancer Therapy

49. Supplementary Figure 5 from The Pivotal Role of Integrin β1 in Metastasis of Head and Neck Squamous Cell Carcinoma

50. Supplementary Figure from Phase II Multi-institutional Clinical Trial Result of Concurrent Cetuximab and Nivolumab in Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma

Catalog

Books, media, physical & digital resources